Welcome to our dedicated page for Recursion Pharmaceuticals news (Ticker: RXRX), a resource for investors and traders seeking the latest updates and insights on Recursion Pharmaceuticals stock.
Recursion Pharmaceuticals, Inc. (RXRX) is a clinical-stage biotechnology pioneer using machine learning and automated experiments to transform drug discovery. This page serves as the definitive source for all official company announcements and verified news coverage.
Investors and industry professionals will find timely updates including clinical trial developments, strategic partnerships, and financial results. Our curated collection features press releases on therapeutic advancements, regulatory milestones, and technology innovations from Recursion's proprietary platform.
Key content categories include quarterly earnings reports, research collaborations, pipeline updates, and executive leadership announcements. All materials are sourced directly from company filings and reputable financial news outlets to ensure accuracy.
Bookmark this page for streamlined access to RXRX's latest progress in decoding complex diseases through computational biology. Check regularly for real-time updates on one of biotech's most technologically advanced drug discovery efforts.
Recursion (Nasdaq: RXRX) announced significant advancements in its clinical trials and financial results for Q1 2022. The company initiated dosing in its Phase 2 trial for cerebral cavernous malformation (CCM) and plans to start a Phase 2/3 trial for NF2-mutated meningiomas in Q2 2022. REC-4881 received Fast Track designation for familial adenomatous polyposis (FAP), with a Phase 2 trial set for Q3 2022. Financially, Q1 2022 revenues reached $5.3 million, up from $2.6 million year-over-year, although R&D expenses rose to $32.4 million, contributing to a net loss of $56.0 million.
Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company, has announced its participation in the Bank of America 2022 Healthcare Conference, taking place from May 10 to May 13, 2022. This event will showcase Recursion's innovative approach to drug discovery through its Recursion Operating System, which integrates advanced technologies and vast datasets. Recursion aims to transform medicine by leveraging machine learning and running millions of experiments weekly. Webcasts will be available on the company's investor website.
Recursion (NASDAQ: RXRX) has received FDA Fast Track designation for its drug candidate REC-4881, aimed at treating familial adenomatous polyposis (FAP) in patients post-colectomy. This allosteric small molecule inhibitor targets MEK1 and MEK2, intended to reduce polyp burden and prevent progression to adenocarcinoma. The designation facilitates expedited drug review, enabling earlier access for patients upon approval. A Phase 2 trial for REC-4881 is set to enroll patients in Q3 2022, marking a significant step towards addressing the unmet needs in FAP treatment.
Recursion (NASDAQ: RXRX), a clinical-stage biotechnology firm, announced its participation in three upcoming investor conferences. These include the Piper Sandler AI/Machine Learning Conference on April 1, 2022, the 21st Annual Needham Virtual Healthcare Conference from April 11-14, 2022, and the Berenberg Discover AI Seminar 2022 on April 26, 2022. The conferences are aimed at showcasing Recursion's advancements in drug discovery, leveraging its extensive biological and chemical datasets. Interested parties can access live webcasts via the investor section of Recursion's website.
Altitude Lab has announced that its inaugural cohort of startups has successfully raised $54 million in seed funding, marking the largest seed financing for life science startups in Utah's history. This incubation initiative, founded in partnership with Recursion and the University of Utah's PIVOT Center, focuses on supporting early-stage healthcare startups. With six out of seven startups securing financing within 18 months, the program emphasizes collaboration with biopharma and health systems, fostering growth in Utah's BioHive ecosystem.
Recursion (NASDAQ: RXRX) announced significant growth and collaborations in its press release on March 23, 2022. The company partnered with Roche and Genentech to develop up to 40 novel medicines, with an upfront payment of $150 million. Recursion expanded its collaboration with Bayer to explore over a dozen fibrosis programs. Additionally, the company initiated its Phase 2 clinical trial for CCM and advanced various oncology therapeutics. Financially, Recursion reported a net loss of $64.9 million for Q4 2021, a significant increase from the previous year.
Recursion (NASDAQ: RXRX) has achieved a significant milestone by enrolling the first patient in its Phase 2 SYCAMORE clinical trial for REC-994, a novel small molecule aimed at treating cerebral cavernous malformation (CCM). CCM affects approximately 360,000 symptomatic patients in the U.S. and EU5. The trial is a multi-center, randomized, double-blind study expected to enroll around 60 subjects, focusing on the safety, efficacy, and pharmacokinetics of REC-994. This marks the first industry-sponsored human efficacy trial for CCM, highlighting the urgent need for effective therapies in this patient population.
Recursion (NASDAQ: RXRX) updated its clinical trial guidance, including a significant delay for a Phase 2 trial of REC-3599 in Tay-Sachs disease, now expected to start in approximately two years. However, the company is on track for several other trials: REC-994 for Cerebral Cavernous Malformation, REC-2282 for Neurofibromatosis Type 2, and REC-4881 for Familial Adenomatous Polyposis, with expected patient enrollment in Q2 2022. Preparations for a Phase 1 study of REC-3964 in recurrent C. difficile colitis are also proceeding as planned, aiming for enrollment in the second half of 2022.
Recursion (NASDAQ: RXRX), a biotechnology firm focused on drug discovery, announced its participation in two major investor conferences:
- KeyBanc Capital Markets Emerging Technology Summit — March 8-9, 2022
- SVB Leerink Mountain Meeting — March 20-23, 2022
Webcasts will be accessible via the investor section on their website. Recursion utilizes advanced technologies to enhance drug discovery, boasting one of the largest biological datasets and powerful computational resources, aiming to revolutionize medicine.
FAQ
What is the current stock price of Recursion Pharmaceuticals (RXRX)?
What is the market cap of Recursion Pharmaceuticals (RXRX)?
